Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,740.00
+140.00 (5.38%)
At close: Jul 6, 2026
Market Cap253.95B +181.7%
Revenue (ttm)3.42B -74.2%
Net Income-10.14B
EPS-128.50
Shares Out 94.05M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,615,578
Open2,640.00
Previous Close2,600.00
Day's Range2,620.00 - 3,000.00
52-Week Range1,080.00 - 4,690.00
Beta0.41
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 97
Stock Exchange KOSDAQ
Ticker Symbol 217730
Full Company Profile

Financial Performance

In 2025, Kangstem Biotech's revenue was 3.57 billion, a decrease of -53.88% compared to the previous year's 7.75 billion. Losses were -10.48 billion, 36.7% more than in 2024.

Financial Statements